Caricamento...
Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy
Background: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with human epidermal growth factor receptor 2-negative (HER2(−)) advanced breast cancer is unclear. Patients and Methods: We retrospectively investigated 301 patients with HER2(−) ABC who recei...
Salvato in:
| Pubblicato in: | In Vivo |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
International Institute of Anticancer Research
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7279844/ https://ncbi.nlm.nih.gov/pubmed/32354934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11917 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|